University of Leicester
Browse

Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy

Download (271.32 kB)
journal contribution
posted on 2019-03-20, 09:57 authored by Umesh T. Kadam, Isobel Roberts, Simon White, Ruth Bednall, Kamlesh Khunti, Peter M. Nilsson, Claire A. Lawson
With older and ageing populations, patients experience multiple chronic diseases at the same time. Individual chronic disease guidelines often recommend pharmacological therapies as a key intervention, resulting in patients being prescribed multiple regular medications for their different diseases. Whilst the term 'polypharmacy' has been applied to the use of multiple medications, there is no consistent definition and this term is now being used all inclusively. To improve both scientific rigor and optimal patient care, it is crucial that a standard terminology is used which reclassifies the term 'polypharmacy' into distinct phenotypes relating to the index chronic disease, additional conditions to the index ('comorbidity') or the experience of multiple chronic conditions at the same time (multimorbidity). Using three exemplar index conditions; heart failure, type 2 diabetes and breast cancer, we propose the reclassification of the term 'polypharmacy' into three distinct phenotypes. First, index drug or multi-index drug therapy, where each index condition creates multiple drug use for that condition; second, co-drug therapy, where addition of other comorbid conditions increases the multiple drug use and may influence the management of the index disease and third, multi drug therapy, where adult population with multimorbidity may be on many drugs. This paper reviews guidelines for the individual exemplars to develop the basis for the new terms and then develops the pharmaco-epidemiology of multiple drug use further by reviewing the evidence on the relationship between the phenotypic classification and important outcomes. The importance of standardising 'polypharmacy' terminology for the scientific agenda and clinical practice is that it relates to an index condition or disease safety outcomes including drug interactions, adverse side effects in hospital admissions and related 'polypill' concept.

Funding

CAL is supported by the University of Leicester Wellcome Trust Institutional Strategic Support Fund.

History

Citation

Journal of Clinical Epidemiology, 2019, 106, pp. 98-107

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Health Sciences

Version

  • AM (Accepted Manuscript)

Published in

Journal of Clinical Epidemiology

Publisher

Elsevier

eissn

1878-5921

Acceptance date

2018-10-24

Copyright date

2018

Available date

2019-10-29

Publisher version

https://www.sciencedirect.com/science/article/pii/S0895435617314427?via=ihub

Notes

The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC